enGene Holdings Inc. (NASDAQ:ENGN – Get Free Report) major shareholder Growth Opportunities F. Forbion acquired 2,750 shares of the firm’s stock in a transaction that occurred on Wednesday, December 27th. The stock was acquired at an average price of $7.17 per share, with a total value of $19,717.50. Following the completion of the transaction, the insider now directly owns 2,002,750 shares in the company, valued at $14,359,717.50. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
enGene Price Performance
Shares of ENGN opened at $9.02 on Friday. The company has a 50 day moving average of $6.71 and a 200-day moving average of $9.78. The company has a quick ratio of 19.52, a current ratio of 19.52 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $398.38 million, a P/E ratio of -5.24 and a beta of -0.69. enGene Holdings Inc. has a twelve month low of $4.42 and a twelve month high of $43.00.
enGene (NASDAQ:ENGN – Get Free Report) last issued its quarterly earnings results on Tuesday, September 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.05. As a group, equities research analysts forecast that enGene Holdings Inc. will post -1.56 EPS for the current fiscal year.
Analysts Set New Price Targets
Check Out Our Latest Stock Analysis on ENGN
Institutional Trading of enGene
Institutional investors and hedge funds have recently bought and sold shares of the stock. Janus Henderson Group PLC bought a new position in enGene in the first quarter valued at approximately $17,095,000. SR One Capital Management LP acquired a new stake in shares of enGene in the 2nd quarter valued at approximately $4,715,000. Logos Global Management LP grew its stake in shares of enGene by 50.0% in the second quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock valued at $11,316,000 after buying an additional 400,000 shares in the last quarter. Finally, Altitude Crest Partners Inc. acquired a new position in enGene during the first quarter worth $2,039,000. Institutional investors own 64.16% of the company’s stock.
enGene Company Profile
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
Further Reading
- Five stocks we like better than enGene
- CD Calculator: Certificate of Deposit Calculator
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- What is the Dow Jones Industrial Average (DJIA)?
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
- How to Capture the Benefits of Dividend Increases
- MarketBeat Week in Review – 10/14 – 10/18
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.